A G358S mutation in the Plasmodium falciparum Na(+) pump PfATP4 confers clinically-relevant resistance to cipargamin

Diverse compounds target the Plasmodium falciparum Na(+) pump PfATP4, with cipargamin and (+)-SJ733 the most clinically-advanced. In a recent clinical trial for cipargamin, recrudescent parasites emerged, with most having a G358S mutation in PfATP4. Here, we show that PfATP4(G358S) parasites can wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Deyun, Pei, Jinxin V., Rosling, James E. O., Thathy, Vandana, Li, Dongdi, Xue, Yi, Tanner, John D., Penington, Jocelyn Sietsma, Aw, Yi Tong Vincent, Aw, Jessica Yi Han, Xu, Guoyue, Tripathi, Abhai K., Gnadig, Nina F., Yeo, Tomas, Fairhurst, Kate J., Stokes, Barbara H., Murithi, James M., Kümpornsin, Krittikorn, Hasemer, Heath, Dennis, Adelaide S. M., Ridgway, Melanie C., Schmitt, Esther K., Straimer, Judith, Papenfuss, Anthony T., Lee, Marcus C. S., Corry, Ben, Sinnis, Photini, Fidock, David A., van Dooren, Giel G., Kirk, Kiaran, Lehane, Adele M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525273/
https://www.ncbi.nlm.nih.gov/pubmed/36180431
http://dx.doi.org/10.1038/s41467-022-33403-9

Ejemplares similares

Ejemplares similares